Condition: Acute Respiratory Failure · Endothelial Dysfunction · Pulmonary Infection · Sponsor: Pär Johansson
The purpose of this clinical trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 450 mechanically ventilated patients with infectious respiratory failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in patients suffering from respiratory failure caused by endothelial breakdown, ultimately improving survival.
This description comes directly from the study's public registry record.
Pär I Johansson, MD, DMSc · +4535452030 · per.johansson@regionh.dk
Kristine H Pedersen, MSc. Pharm. · +4535453489 · kristine.holst.pedersen.01@regionh.dk
Always discuss trial participation with your own doctor first.
| Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital | Copenhagen, Denmark | Recruiting |
| Dept. of Intensive Care, Copenhagen University Hospital Herlev | Herlev, Denmark | Recruiting |
| Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital | Hillerød, Denmark | Recruiting |
| Dept. of Intensive care, Hvidovre Hospital | Hvidovre, Denmark | Recruiting |
| Department of Anesthesia and Intensive Care Medicine, Zealand University Hospital | Køge, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06319274